The effects of antipsychotic drugs have generally been considered to be mediated by blockade of dopamine D 2 receptors. The concept of limbic and cortical selectivity of second-generation antipsychotics, i.e. higher dopamine D 2 receptor occupancy in the cerebral cortices than in the striatum, has been suggested to explain their clinical efficacy with lower incidence of extrapyramidal side-effects. In this study, regional distribution of dopamine D 2 receptor occupancy by risperidone was determined in order to elucidate the limbic and cortical selectivity of second-generation antipsychotics. Striatal and extrastriatal dopamine D 2 receptor binding at baseline and after oral administration of 2 mg risperidone were measured in ten healthy men by positron emission tomography (PET) using different tracers with different affinity for the receptors, [
Introduction
The effects of antipsychotic drugs have been widely considered to be mediated by blockade of dopamine D 2 receptors (Carlsson and Lindqvist, 1963 ; Creese et al., 1976 ; Seeman et al., 1976) . This hypothesis has been supported by positron emission tomography (PET) studies to determine dopamine D 2 receptor occupancy in patients with schizophrenia treated with typical antipsychotics, so-called first-generation antipsychotics, e.g. haloperidol (Baron et al., 1989 ; Farde et al., 1988) . Atypical antipsychotics, so-called second-generation antipsychotics, e.g. clozapine, risperidone, and olanzapine, which show lower risk of drug-induced extrapyramidal side-effects than first-generation antipsychotics (Gerlach, 1991 ; Meltzer et al., 1989) , have been broadly used in the treatment of schizophrenia in recent years. To explain the clinical properties of second-generation antipsychotics, several hypotheses have been proposed. Blockade of neuroreceptors other than dopamine D 2 receptors, in particular 5-HT 2A receptors, has been suggested to reduce extrapyramidal side-effects (Balsara et al., 1979 ; Hicks, 1990 ; Korsgaard et al., 1985) . Fast dissociation from dopamine D 2 receptors has been suggested to explain the lower incidence of extrapyramidal side-effects in some second-generation antipsychotics (Kapur and Seeman, 2001 ). The concept of limbic and cortical selectivity of second-generation antipsychotics, i.e. higher dopamine D 2 receptor occupancy in the cerebral cortices than in the striatum, has also been suggested to explain their clinical efficacy with few extrapyramidal side-effects (Pilowsky et al., 1997) .
Limbic and cortical selectivity was originally observed in dopamine D 2 receptor occupancy by clozapine in patients with schizophrenia using [
123 I]epidepride (Pilowsky et al., 1997) , [ 76 Br]FLB 457 (Xiberas et al., 2001 ) and [
18 F]fallypride (Grunder et al., 2006 ; Kessler et al., 2006) . Limbic and cortical selectivity was also reported in other second-generation antipsychotics, e.g. risperidone using [
76 Br]FLB 457 (Xiberas et al., 2001 ) and [
123 I]epidepride , olanzapine using [
76 Br]FLB 457 (Xiberas et al., 2001) , and quetiapine using [
18 F]fallypride (Kessler et al., 2006) in patients with schizophrenia. On the other hand, no differences in occupancy of dopamine D 2 receptors between the cerebral cortices and striatum were observed in patients with schizophrenia taking clozapine (Talvik et al., 2001) or 9-hydroxyrisperidone (paliperidone) . In those studies, binding to receptors in striatal and extrastriatal regions, in which densities of dopamine D 2 receptors were quite different (Hall et al., 1994) , were determined by [
11 C]raclopride and [ 11 C]FLB 457, respectively. In addition, limbic and cortical selectivity was not supported using [
18 F]fallypride with olanzapine in patients with schizophrenia (Kessler et al., 2005) and with clozapine and risperidone in animals (Mukherjee et al., 2001 ). However, in most studies concerning the regional selectivity of dopamine D 2 receptor occupancy in patients with schizophrenia, baseline binding to receptors for the calculation of occupancy were binding of other healthy subjects, not the binding of the neuroleptic naive state of the same patients.
In the present study, to elucidate the regional difference in dopamine D 2 receptor occupancy by second-generation antipsychotics, regional occupancy by risperidone was determined in healthy human subjects. Striatal and extrastriatal dopamine D 2 receptor binding at baseline and after oral administration of drug were measured in the same subjects by PET. Because dopamine D 2 receptor density is quite different between the striatal and extrastriatal regions (Hall et al., 1994 (Hall et al., , 1996 , striatal and extrastriatal dopamine D 2 receptor binding were measured by different tracers with different affinity for the receptors, [
11 C]raclopride and [ 11 C]FLB 457, respectively (Farde et al., 1995 ; Suhara et al., 1999) .
Materials and methods

Subjects
The study was approved by the Ethics and Radiation Safety Committees of the National Institute of Radiological Sciences, Chiba, Japan. Ten healthy men [20-37 yr, 26.9¡5.6 (mean¡S.D.) ] were recruited and written informed consent was obtained. The subjects were free of somatic, neurological or psychiatric disorders on the basis of their medical history and magnetic resonance (MR) imaging of the brain. They had no history of current or previous drug abuse.
PET procedures
All PET studies were performed with a Siemens ECAT Exact HR+ system, which provides 63 sections with an axial field of view of 15.5 cm (Brix et al., 1997) . The intrinsic spatial resolution was 4.3 mm in-plane and 4.2 mm full-width at half maximum (FWHM) axially. With a Hanning filter (cut-off frequency : 0.4 cycle/pixel), the reconstructed in-plane resolution was 7.5 mm FWHM. Data were acquired in threedimensional mode. Scatter was corrected (Watson et al., 1996) . A 10-min transmission scan using a 68 Ge-68 Ga line source was performed for correction of attenuation. A head fixation device with thermoplastic attachments for individual fit minimized head movement during PET measurements.
PET studies were performed under resting condition (baseline study) and oral administration of risperidone (drug challenge study) on separate days. The interval between the two studies was 7 d in six subjects, 21 d in two subjects, 28 d in one subject, and 4 months in one subject. In each study, both PET scans with [ 11 C]FLB 457, respectively. The injected mass of raclopride and FLB 457 was 0.74-1.82 nmol and 0.87-1.37 nmol in baseline studies, and 0.87-2.66 nmol and 0.98-1.61 nmol in drug challenge studies, respectively.
In the drug challenge study, 2 mg risperidone was orally administered at 2 h before the start of PET scanning with [
11 C]raclopride. To estimate the plasma concentration of risperidone and its active metabolite (9-hydroxy-risperidone), venous blood samplings were performed at the start and end of each PET scanning. The plasma concentrations of risperidone and 9-hydroxy-risperidone were determined by a validated liquid chromatography coupled to mass spectrometry/mass spectrometry (LC-MS/MS) method. Since risperidone and 9-hydroxy-risperidone have similar binding profiles to neuroreceptors (Leysen et al., 1994) , the sum of their plasma concentrations was used as the plasma concentration of antipsychotic drug in the present study.
All MR imaging studies were performed with a 1.5-T MR scanner (Philips Medical Systems, Best, The Netherlands). Three-dimensional volumetric acquisition of a T 1 -weighted gradient echo sequence produced a gapless series of thin transverse sections (TE 9.2 ms ; TR 21 ms ; flip angle 30x ; field of view 256 mm ; acquisition matrix 256r256 ; slice thickness 1 mm).
Regions of interest (ROIs)
The MR images were co-registered to each of summation images of all frames of dynamic PET scans for a subject with the statistical parametric mapping (SPM2) system (Friston et al., 1990) . ROIs were drawn on co-registered MR images and transferred to the PET images. ROIs were defined for the cerebellar cortex, midbrain, thalamus, caudate head, putamen, parahippocampal gyrus including amygdala, anterior part of the cingulate gyrus, frontal cortex, temporal cortex, and parietal cortex. Each ROI was drawn in three adjacent sections and data were pooled to obtain the average radioactivity concentration for the whole volume of interest. To obtain regional time-activity curves, regional radioactivity was calculated for each frame, corrected for decay, and plotted vs. time.
Calculation of dopamine D 2 receptor occupancy
For both PET studies with [
11 C]raclopride and [
11 C]FLB 457, the binding potential (BP ND ) was calculated by the reference tissue model method . With this method, the time-activity curve in the brain region is described by that in the reference region with no specific binding, assuming that both regions have the same level of non-displaceable radioligand binding :
where C i is the radioactivity concentration in a brain region, C r (t) is the radioactivity concentration in the reference region, R I is the ratio of K 1 /K 1 ' (K 1 , influx rate constant for the brain region ; K 1 ', influx rate constant for the reference region), k 2 is the efflux rate constant for the brain region, and denotes the convolution integral. In this analysis, three parameters (BP ND , R I , and k 2 ) were estimated by nonlinear least-squares curve fitting. The cerebellum was used as reference region. Dopamine D 2 receptor occupancy by risperidone was calculated as follows :
where BP ND, baseline is BP ND in the baseline study, and BP ND, drug is BP ND in the drug challenge study. The relation between the plasma concentration of antipsychotic drug and dopamine D 2 receptor occupancy can be expressed as follows (Kapur and Remington, 1996 ; Takano et al., 2004) :
where C is the sum of plasma concentrations of risperidone and 9-hydroxy-risperidone, and ED 50 is the plasma concentration required to induce 50 % occupancy.
Anatomic standardization
The analysis using ROI does not allow evaluation of data throughout the brain. For visualization of regional differences in dopamine D 2 receptor occupancy, inter-subject averaging of occupancy images, which requires transformation of brain images of individual subjects into a standard brain shape and size in three dimensions (anatomical standardization), was performed (Fox et al., 1988) . BP ND images of [ 11 C]raclopride and [ 11 C]FLB 457 were calculated on a voxel-by-voxel basis by the reference tissue model with the basis function method (Gunn et al., 1997) . Images of dopamine D 2 receptor occupancy were also calculated on a voxel-by-voxel basis. All MR Dopamine D 2 receptor occupancy by antipsychotics 669 by guest on November 7, 2016 http://ijnp.oxfordjournals.org/ images that were co-registered to the PET images were transformed into the standard brain size and shape by linear and nonlinear parameters with SPM2 (Friston et al., 1990) . The brain templates used in SPM2 for the anatomical standardization were T 1 templates for MR images. All PET images were also transformed into the standard brain size and shape by the use of same parameters as MR images. Thus, brain images of all subjects had the same anatomical format. Average images for BP ND and dopamine D 2 receptor occupancy were calculated on a voxel-by-voxel basis.
Simulation study
Although specific [
11 C]FLB 457 binding in the cerebellum was not supported statistically in previous studies (Olsson et al., 1999 ; Suhara et al., 1999) , the BP ND value for the cerebellum has been reported to be small but not zero ). It has recently been reported that a non-negligible density of dopamine D 2 receptors in the cerebellum led to the underestimation of BP ND in a brain region as well as errors in dopamine D 2 receptor occupancy in [
11 C]FLB 457 PET studies (Asselin et al., 2007) . To estimate such errors in the occupancy of receptors calculated by methods using data of the reference region, i.e. cerebellum, in a [
11 C]FLB 457 PET study, a simulation study was performed.
For the baseline study, the total distribution volume V T in the reference region was calculated from the distribution volume for non-displaceable binding (V ND ) of 3 ml/ml and BP ND of 0.1-0.5 in five steps as V T =V ND (1+BP ND ) . V T in the target region was also calculated with V ND =3 ml/ml and BP ND =3. V T in the drug challenge study for both the target and reference regions was calculated with BP ND that was varied with occupancy of 0-100 % and equal across regions. From the total distribution volume ratio (DVR) of the target region to the reference region, the estimated dopamine D 2 receptor occupancy was calculated as follows :
These estimated occupancy values were compared with the assumed values which were occupancy values varied in the target brain region without consideration of specific binding in the cerebellum.
Results
Striatal and extrastriatal BP ND values and dopamine D 2 receptor occupancy are shown in Tables 1 and 2 .
The ranges of dopamine D 2 receptor occupancy are 71-76 % and 56-60 % for the striatum and extrastriatum without the midbrain, respectively. No druginduced extrapyramidal side-effects were observed in any of subjects. Although direct comparisons of dopamine D 2 receptor occupancy between striatal and extrastriatal regions may not be appropriate due to systematic errors in occupancy for [ 11 C]FLB 457 studies as mentioned below, dopamine D 2 receptor occupancy in the caudate head was significantly higher than that in midbrain, thalamus, anterior cingulate, and parietal cortex after correction of multiple comparisons (p<0.05). Dopamine D 2 receptor occupancy in the putamen was significantly higher than that in the thalamus. No significant differences in the radioactivity injected, specific radioactivity, and injected mass were observed between baseline and drug challenge studies for both [ Figures 1 and 2 . The visualization of regional differences in dopamine D 2 receptor occupancy throughout the brain was allowed by intersubject averaging of images. Among extrastriatal regions, no obvious regional differences in dopamine D 2 receptor occupancy were observed. In the striatum, no obvious regional differences in occupancy were also observed. The sum of the plasma concentrations of risperidone and 9-hydroxy-risperidone during [
11 C]FLB 457 PET studies, averaged between the start and end of each scanning, was 17.5¡5.2 ng/ ml and 14.5¡4.2 ng/ml (mean¡S.D.), respectively. The ED 50 values were 5.1-6.4 ng/ml for the striatum and 9.0-10.9 ng/ml for the cerebral cortical regions.
Relation between the assumed and estimated dopamine D 2 receptor occupancy for [
11 C]FLB 457 in simulation studies is shown in Figure 3 . Systematic underestimation in estimated occupancy was caused by specific binding in the reference region.
Discussion
The concept of limbic and cortical selectivity of second-generation antipsychotics, namely, higher dopamine D 2 receptor occupancy in the cerebral cortices than in the striatum, has been suggested (Pilowsky et al., 1997) , and limbic and cortical selectivity was reported in risperidone using [ 76 Br]FLB 457 (Xiberas et al., 2001) 
and [
123 I]epidepride .
In the present study, dopamine D 2 receptor occupancy in the striatum was higher than that in the cerebral cortices. The ED 50 values were also lower in the striatum than in the cerebral cortices corresponding with previous reports that ED 50 of risperidone was 6.87 ng/ ml in the striatum (Nyberg et al., 1999) and 7.43 ng/ml in the cerebral cortices (Yasuno et al., 2001) ]raclopride, and T 1 -weighted images. In the striatum, no obvious regional differences in dopamine D 2 receptor occupancy were observed. cerebellum was 0.3 ) and assumed occupancy was 70 %. This indicates that the occupancies of dopamine D 2 receptors in both the striatum and extrastriatum may not have differed. In the present study, [
11 C]FLB 457 PET studies were begun 2 h after the start of [ 11 C]raclopride PET studies, and therefore, the sum of the plasma concentrations of risperidone and 9-hydroxy-risperidone was slightly lower during [ 11 C]FLB 457 studies (14.5¡4.2 ng/ml) than during [
11 C]raclopride studies (17.5¡5.2 ng/ml). When ED 50 is 6 ng/ml, 17.5 and 14.5 ng/ml of the sum of plasma concentrations of risperidone and 9-hydroxyrisperidone reveal 74 % and 71 % of dopamine D 2 receptor occupancy, respectively [eqn (3)]. This might be able to partially explain higher dopamine D 2 receptor occupancy in the [ 11 C]raclopride studies than in the [ 11 C]FLB 457 studies. In addition, it has been reported that the half-life of the sum of plasma concentrations of risperidone and 9-hydroxy-risperidone was about 18 h, and that high dopamine D 2 receptor occupancy was sustained (Takano et al., 2004) , indicating that the effects of differences in plasma concentrations of risperidone and 9-hydroxy-risperidone between [ 11 C]raclopride and [ 11 C]FLB 457 studies on the occupancies of dopamine D 2 receptors might be very small.
Several mechanisms for the limbic and cortical selectivity in dopamine D 2 receptor occupancy by the second-generation antipsychotic risperidone have been proposed . One possible mechanism was that risperidone also bound to dopamine D 3 receptors (Arnt and Skarsfeldt, 1998) , which were highly expressed in limbic regions (Joyce, 2001) . However, the occupancies of dopamine D 2 receptors by risperidone in both the striatum and extrastriatum may not have differed in the present study. Because dopamine D 2 receptor density is quite different between the striatal and extrastriatal regions (Hall et al., 1994 (Hall et al., , 1996 , it should be appropriate to determine striatal and extrastriatal binding by different tracers with different affinity for receptors whereas both striatal and extrastriatal binding were determined by same tracer in previous reports supporting limbic and cortical selectivity of risperidone Xiberas et al., 2001 ). The dissociation constant K D , indicating affinity for receptors in the living human brain was quite different between [
11 C]FLB 457, i.e. about 10 nM with the former (Farde et al., 1995) and 1 nM with the latter (Suhara et al., 1999) . Talvik and colleagues stated that a simple ratio approach using a high-affinity radioligand such as [
123 I]epidepride without validation of equilibrium conditions might yield an underestimation of D 2 receptor occupancy in the striatum in comparison with the D 2 receptor occupancy in the extrastriatal regions (Talvik et al., 2001) . Although non-negligible specific binding in the cerebellum and differences in plasma concentrations of risperidone and 9-hydroxyrisperidone between studies cause systematic errors in occupancy, the use of two tracers with different affinities, [
11 C]raclopride and [ 11 C]FLB 457, must be superior compared with the use of one tracer to determine the occupancy in both the striatum and extrastriatum. Erlandsson et al. (2003) reported that too short a data acquisition time in [
11 C]FLB 457 PET studies could cause an underestimation of occupancy in extrastriatal regions. However, the accuracy of estimation of extrastriatal BP ND and occupancy in [ 11 C]FLB 457 studies with a data acquisition time of over 60 min was confirmed Olsson and Farde, 2001 ; Olsson et al., 1999 ; Sudo et al., 2001) . The accuracy of estimation of striatal BP ND using [ 11 C]raclopride was also confirmed (Ito et al., 1998 ; . Although direct comparisons of dopamine D 2 receptor occupancy between striatal and extrastriatal regions determined by different tracers may not be appropriate due to systematic errors in occupancy for [ 11 C]FLB 457 studies as mentioned above (Kessler and Meltzer, 2002) , limbic and cortical selectivity of risperidone was not supported in the present study with healthy subjects.
Among extrastriatal regions including limbic and neocortical regions, no significant regional differences in dopamine D 2 receptor occupancy by risperidone were observed. In the striatum, no obvious regional differences in occupancy were also observed.
Although the density of dopamine D 2 receptors varies in these regions , dopamine D 2 receptor occupancy by antipsychotics is independent of receptor density. These data indicate that the concentrations of risperidone and 9-hydroxy-risperidone in tissue may be uniform throughout the brain. If the dissociation constant of antipsychotic drug to dopamine D 2 receptors would regionally change in patients, the occupancy by antipsychotic drug would be regionally changed. However, to our knowledge, there are no reports about regional changes in dissociation constant of antipsychotic drugs in patients.
Second-generation antipsychotics have been suggested to have clinical efficacy with few extrapyramidal side-effects compared with first-generation antipsychotics (Balsara et al., 1979 ; Hicks, 1990 ; Kapur and Seeman, 2001 ; Korsgaard et al., 1985 ; Pilowsky et al., 1997) . However, a recent randomized controlled trial has shown no differences in the effects on the quality of life between first-and second-generation antipsychotics (Jones et al., 2006) . For antipsychotic therapy with less extrapyramidal side-effects, the determination of adequate clinical dosage of antipsychotics by measuring dopamine D 2 receptor occupancy using PET may be important whether for first-or second-generation antipsychotics (Farde et al., 1992 ; Takano et al., 2006) .
In conclusion, striatal and extrastriatal occupancies of dopamine D 2 receptors after oral administration of a second-generation antipsychotic drug, risperidone, were measured in healthy subjects by PET with [
11 C]raclopride and [ 11 C]FLB 457, respectively. Higher dopamine D 2 receptor occupancy in the cerebral cortices than in the striatum was not observed, and the concept of limbic and cortical selectivity of the secondgeneration antipsychotic drug risperidone was not supported in the present study.
